Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Receivables (2016 - 2025)

Dexcom (DXCM) has disclosed Change in Receivables for 16 consecutive years, with $106.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 1335.14% to $106.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $201.9 million, a 476.86% increase, with the full-year FY2025 number at $201.9 million, up 476.86% from a year prior.
  • Change in Receivables was $106.2 million for Q4 2025 at Dexcom, up from -$237.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $187.2 million in Q4 2023 to a low of -$237.8 million in Q3 2025.
  • A 5-year average of $38.6 million and a median of $32.9 million in 2021 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 2467.24% in 2025; the steepest drop was 527.7% in 2025.
  • Dexcom's Change in Receivables stood at -$15.1 million in 2021, then soared by 1082.12% to $148.3 million in 2022, then rose by 26.23% to $187.2 million in 2023, then tumbled by 96.05% to $7.4 million in 2024, then skyrocketed by 1335.14% to $106.2 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Change in Receivables are $106.2 million (Q4 2025), -$237.8 million (Q3 2025), and $184.6 million (Q2 2025).